Stay updated with breaking news from Roger Nitsch. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Lonza Group AG / Key word(s): AGMEGM Lonza Publishes Invitation to the 2023 Annual General Meeting and 2022 Annual and Sustainability Reports 27-March-2023 / 07:00 CET/CEST Release of an ad hoc announcement
Aducanumab is approved in the United States, but the EU's regulatory authority is blocking its use. The drug is designed to combat amyloid beta plaques in the brain that are typical of Alzheimer's disease.
The drug aducanumab could be approved in the US and EU soon. It effectively combats the amyloid beta plaques in the brain that are indicative of Alzheimer's disease. But does it also slow down memory loss?
The drug aducanumab could be approved in the US and EU soon. It effectively combats the amyloid beta plaques in the brain that are indicative of Alzheimer's disease. But does it also slow down memory loss?
07 Apr 2021 Part 2 of a two-part story. Click here for Part 1. The COVID-19 pandemic has touched every aspect of health, from neurologic disease broadly (see Part 1 of this story) to clinical research. At the 15th International Conference on Alzheimer's and Parkinson's Diseases, held virtually March 9–14, clinical investigators talked about how they tried to prevail despite interruptions and preserve their trials. Looking to the future, how they will handle people who had COVID-19, or develop it during a trial, remains unclear. Home nursing allowed dosing to continue in Roche's gantenerumab...